Annual CFF
$15.79 M
+$296.00 K+1.91%
31 December 2023
Summary:
NovoCure Limited annual cash flow from financing activities is currently $15.79 million, with the most recent change of +$296.00 thousand (+1.91%) on 31 December 2023. During the last 3 years, it has fallen by -$424.42 million (-96.41%). NVCR annual CFF is now -96.41% below its all-time high of $440.21 million, reached on 31 December 2020.NVCR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$100.00 K
-$87.22 M-99.89%
30 September 2024
Summary:
NovoCure Limited quarterly cash flow from financing activities is currently $100.00 thousand, with the most recent change of -$87.22 million (-99.89%) on 30 September 2024. Over the past year, it has dropped by -$1.07 million (-91.46%). NVCR quarterly CFF is now -99.98% below its all-time high of $570.85 million, reached on 31 December 2020.NVCR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$89.54 M
-$1.07 M-1.18%
30 September 2024
Summary:
NovoCure Limited TTM cash flow from financing activities is currently $89.54 million, with the most recent change of -$1.07 million (-1.18%) on 30 September 2024. Over the past year, it has increased by +$72.25 million (+417.96%). NVCR TTM CFF is now -84.90% below its all-time high of $592.90 million, reached on 30 September 2021.NVCR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVCR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.9% | -91.5% | +418.0% |
| 3 y3 years | -96.4% | -96.7% | -84.9% |
| 5 y5 years | -77.2% | -99.3% | +60.9% |
NVCR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -96.4% | +1.9% | -99.9% | at low | -84.9% | +729.4% |
| 5 y | 5 years | -96.4% | +1.9% | -100.0% | +100.1% | -84.9% | +173.4% |
| alltime | all time | -96.4% | +636.0% | -100.0% | +100.1% | -84.9% | +173.4% |
NovoCure Limited Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $100.00 K(-99.9%) | $89.54 M(-1.2%) |
| June 2024 | - | $87.32 M(>+9900.0%) | $90.61 M(+739.3%) |
| Mar 2024 | - | $213.00 K(-88.8%) | $10.80 M(-31.6%) |
| Dec 2023 | $15.79 M(+1.9%) | $1.91 M(+63.1%) | $15.79 M(-8.7%) |
| Sept 2023 | - | $1.17 M(-84.4%) | $17.29 M(-14.9%) |
| June 2023 | - | $7.50 M(+44.2%) | $20.32 M(+15.8%) |
| Mar 2023 | - | $5.20 M(+52.6%) | $17.55 M(+13.3%) |
| Dec 2022 | $15.49 M(-39.7%) | $3.41 M(-18.9%) | $15.49 M(-1.5%) |
| Sept 2022 | - | $4.20 M(-11.2%) | $15.73 M(+8.0%) |
| June 2022 | - | $4.74 M(+50.8%) | $14.56 M(-30.3%) |
| Mar 2022 | - | $3.14 M(-14.0%) | $20.89 M(-18.7%) |
| Dec 2021 | $25.70 M(-94.2%) | $3.65 M(+20.3%) | $25.70 M(-95.7%) |
| Sept 2021 | - | $3.04 M(-72.5%) | $592.90 M(+31.9%) |
| June 2021 | - | $11.06 M(+39.0%) | $449.38 M(+1.3%) |
| Mar 2021 | - | $7.96 M(-98.6%) | $443.66 M(+0.8%) |
| Dec 2020 | $440.21 M(+613.7%) | $570.85 M(-506.3%) | $440.21 M(-460.7%) |
| Sept 2020 | - | -$140.49 M(-2728.5%) | -$122.06 M(-460.0%) |
| June 2020 | - | $5.34 M(+18.7%) | $33.90 M(-31.1%) |
| Mar 2020 | - | $4.50 M(-47.6%) | $49.21 M(-20.2%) |
| Dec 2019 | $61.68 M | $8.59 M(-44.5%) | $61.68 M(+10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $15.47 M(-25.1%) | $55.66 M(+26.2%) |
| June 2019 | - | $20.66 M(+21.7%) | $44.09 M(+27.3%) |
| Mar 2019 | - | $16.97 M(+561.6%) | $34.63 M(-50.1%) |
| Dec 2018 | $69.37 M(+1242.3%) | $2.56 M(-34.3%) | $69.37 M(+1.8%) |
| Sept 2018 | - | $3.90 M(-65.1%) | $68.13 M(+3.3%) |
| June 2018 | - | $11.19 M(-78.4%) | $65.94 M(+16.1%) |
| Mar 2018 | - | $51.71 M(+3791.2%) | $56.82 M(+999.5%) |
| Dec 2017 | $5.17 M(-93.1%) | $1.33 M(-22.4%) | $5.17 M(+0.0%) |
| Sept 2017 | - | $1.71 M(-17.1%) | $5.17 M(-93.2%) |
| June 2017 | - | $2.07 M(+3403.4%) | $76.31 M(+1.6%) |
| Mar 2017 | - | $59.00 K(-95.6%) | $75.14 M(+0.0%) |
| Dec 2016 | $75.12 M(-72.9%) | $1.33 M(-98.2%) | $75.12 M(-68.0%) |
| Sept 2016 | - | $72.85 M(+7976.8%) | $235.05 M(+46.2%) |
| June 2016 | - | $902.00 K(+2100.0%) | $160.76 M(-36.5%) |
| Mar 2016 | - | $41.00 K(-100.0%) | $253.24 M(-8.6%) |
| Dec 2015 | $276.99 M(>+9900.0%) | $161.26 M(<-9900.0%) | $276.99 M(+139.3%) |
| Sept 2015 | - | -$1.44 M(-101.5%) | $115.73 M(-1.2%) |
| June 2015 | - | $93.39 M(+292.6%) | $117.17 M(+392.6%) |
| Mar 2015 | - | $23.79 M | $23.79 M |
| Dec 2014 | $2.15 M(-98.8%) | - | - |
| Dec 2013 | $183.32 M | - | - |
FAQ
- What is NovoCure Limited annual cash flow from financing activities?
- What is the all time high annual CFF for NovoCure Limited?
- What is NovoCure Limited annual CFF year-on-year change?
- What is NovoCure Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for NovoCure Limited?
- What is NovoCure Limited quarterly CFF year-on-year change?
- What is NovoCure Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for NovoCure Limited?
- What is NovoCure Limited TTM CFF year-on-year change?
What is NovoCure Limited annual cash flow from financing activities?
The current annual CFF of NVCR is $15.79 M
What is the all time high annual CFF for NovoCure Limited?
NovoCure Limited all-time high annual cash flow from financing activities is $440.21 M
What is NovoCure Limited annual CFF year-on-year change?
Over the past year, NVCR annual cash flow from financing activities has changed by +$296.00 K (+1.91%)
What is NovoCure Limited quarterly cash flow from financing activities?
The current quarterly CFF of NVCR is $100.00 K
What is the all time high quarterly CFF for NovoCure Limited?
NovoCure Limited all-time high quarterly cash flow from financing activities is $570.85 M
What is NovoCure Limited quarterly CFF year-on-year change?
Over the past year, NVCR quarterly cash flow from financing activities has changed by -$1.07 M (-91.46%)
What is NovoCure Limited TTM cash flow from financing activities?
The current TTM CFF of NVCR is $89.54 M
What is the all time high TTM CFF for NovoCure Limited?
NovoCure Limited all-time high TTM cash flow from financing activities is $592.90 M
What is NovoCure Limited TTM CFF year-on-year change?
Over the past year, NVCR TTM cash flow from financing activities has changed by +$72.25 M (+417.96%)